Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17229355 | 0.81 | GABRA1 (0.43) | DRD2DRD3HTR6HTR2AHTR2C | |
| SCHEMBL27641244 | 0.78 | PNMT (0.49) | HTR2AHTR2C | |
| SCHEMBL21335649 | 0.75 | DRD2 (0.47) | DRD2DRD3HTR6HTR2AHTR2C | |
| SCHEMBL8179926 | 0.75 | DRD2 (0.42) | DRD2DRD3HTR6HTR2AHTR2C | |
| SCHEMBL19891712 | 0.71 | CHRM2 (0.45) | — | |
| SCHEMBL7770508 | 0.70 | ESR1 (0.41) | DRD2DRD3HTR6 | |
| SCHEMBL23095177 | 0.69 | ALDH1A1 (0.36) | DRD2DRD3HTR2A | |
| SCHEMBL6569194 | 0.69 | ALOX15 (0.63) | DRD2DRD3HTR2A | |
| SCHEMBL18583848 | 0.69 | PNMT (0.50) | DRD2DRD3 | |
| SCHEMBL19281909 | 0.69 | ASIC3 (0.50) | DRD2DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | DRD2 3514/4885DRD3 4175/4885HTR6 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.